Pricing
  1. JP-listed companies
  2. Perseus Proteomics Inc.
  3. Financials
  4. EBITDA

Perseus Proteomics Inc. (4882)

Market cap
¥3.3B
P/E ratio
Perseus Proteomics develops high-performance antibodies for cancer treatment and drug discovery using proprietary technology from the University of Tokyo.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 2025-824-7.59%
Mar 31, 2024-891+28.78%
Mar 31, 2023-692+47.49%
Mar 31, 2022-469+13.98%
Mar 31, 2021-412-49.31%
Mar 31, 2020-812+464.03%
Mar 31, 2019-144

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat